| ART | Antiretroviral therapy |
| BCG | Bacillus Calmette–Guérin |
| CAGTA | C. albicans germ tube antibodies |
| DABCO | 1,4-Diazabicyclo[2.2.2]octane |
| DRF | Damage response framework |
| DS | Denture stomatitis |
| DSC | Deep-seated candidiasis |
| GI | Gastrointestinal |
| HDC | Hematogenously disseminated candidiasis |
| HIV | Human immunodeficiency virus |
| HS | Heparan sulfate |
| HSPC | Hematopoietic stem and progenitor cell |
| IAC | Intra-abdominal candidiasis |
| IAI | Intra-abdominal infection |
| ICU | Intensive care unit |
| IFN | Interferon |
| IL | Interleukin |
| MDSC | Myeloid-derived suppressor cell |
| NAC | Non-albicans Candida |
| NSAID | Non-steroidal anti-inflammatory drug |
| nTh17 | Natural T helper type 17 |
| OPC | Oropharyngeal candidiasis |
| PDI | Photodynamic inactivation |
| PMN | Polymorphonuclear neutrophil |
| RVVC | Recurrent vulvovaginal candidiasis |
| SAP | Secretory aspartyl proteinase |
| Th | T helper |
| TII | Trained innate immunity |
| TTI | Trained tolerogenic immunity |
| VVC | Vulvovaginal candidiasis |